Roche reported positive early data on its obesity drug candidate CT-996, showing a 6.1% average weight loss in patients with obesity after four weeks. In the U.S. and globally, insulin shortages are leaving patients with fewer options, with Novo Nordisk discontinuing a product and pharmacies running out of vials. The reasons for the shortages are complex, but it is feared that insulin manufacturers may be less interested in producing it. These issues highlight the challenges patients face in accessing vital medications and the need for continued innovation in the healthcare industry.
Source link
We’re reading about Roche obesity drug data, Menendez verdict
